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ABSTRACT 
Infiltration by CD8+ T cells into the central nervous system (CNS) is a recognized feature in many 
neurodegenerative diseases that are associated with neuroinflammation, such as HIV-associated dementia. The 
frequency of CD8+ T cells in cerebrospinal fluid (CSF) is elevated during HIV infection compared to other 
CNS diseases; however, the role of CD8+ T cells in the CNS during acute infection is unknown. We analyzed 
CD8+ T cells in the CSF from a unique cohort, RV254/SEARCH010, in the earliest stages of acute HIV 
infection. CD8+ T cells in the CSF were elevated in HIV individuals during acute infection compared to 
uninfected. Activated CSF CD8+ T cells positively correlated to CSF viral load and to markers of CNS 
inflammation, neopterin, CD163, and IP-10 whereas activated CSF CD8+ T cells in chronic infection were 
associated with markers of neuronal damage (neurofilament light) and the astroglial activation marker YKL-40. 
Importantly, we showed that CSF CD8+ T cells exhibited a unique restricted TCR Vbeta repertoire and 
contained HIV-specific CD8+ T cells directed to unique HIV epitopes compared to the periphery. Our data 
suggest that although CSF CD8+ T cells in chronic infection are associated with neuropathogenesis, CD8+ T 
cells in hyperacute HIV infection in CSF contain high number of activated cells with increased functional gene 
expression profile and directed against HIV antigens suggesting that could they could play a potential beneficial 
role in early acute infection to prevent development HIV-associated neurocognitive disorders if ART is initiated 
at that stage.  
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BACKGROUND 
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HIV infects the central nervous system (CNS) within days of initial exposure and induces 
neuroinflammation that includes invasion of infected mononuclear cells and subsequent activation of localized 
inflammatory cells such as perivascular macrophages, microglia and astrocytes. These activated CNS resident 
cells release an array of neurotoxins that can be measured in the CSF [1], and additional neuronal injury can 
occur directly from HIV proteins, such as tat and gp120 [2]. This inflammatory environment in the CNS results 
in blood brain barrier permeability, neuronal abnormalities and an increased likelihood for the clinical 
manifestation of HIV-associated neurocognitive disorders (HAND). Antiretroviral therapy (ART) reduces CSF 
HIV RNA levels and changes the pathogenesis of HIV infection, leading to milder forms of HAND without 
impacting its overall prevalence [3, 4]. A critically important recent recognition is that tissue damage persists 
despite ART due to incomplete eradication of HIV reservoirs and sustained CNS inflammation, in part as a 
result of limitations in CNS drug penetration [5-7]. This ongoing injury likely plays a role in a pervasive low-
level encephalopathy presenting as continued mild cognitive impairment [3, 8, 9]. The persistence of HAND in 
the ART era has revealed the critical importance of understanding the key cellular mediators of HIV 
neuropathogenesis in HIV-infected individuals. These cellular mechanisms need to be elucidated to develop 
therapeutic strategies to limit CNS damage and preserve or restore cognitive function in HIV-infected subjects 
before and after ART initiation. 
Infiltration by CD8+ T cells into the CNS is a recognized feature of many neurodegenerative diseases 
associated with neuroinflammation, including multiple sclerosis (MS), Alzheimer’s disease, and various 
encephalitides [10]. CD8+ T cells have been shown to decrease replication of rabies and herpes simplex viruses 
in neurons [11-13]. However, in some virus-induced diseases, CD8+ T cells are involved in direct CNS tissue 
damage [10, 14, 15], and can directly transect neurites in vitro [16]. In MS, the number of CD8+ T cells in 
active lesions correlates with severity of neuronal damage [17], and activated CD8+ T cells are enriched in the 
CSF [18]. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, CD8+ T cells play a 
role in remission, but also induce tissue damage and brain inflammation in chronic EAE [19-21]. Blocking 
CD8+ T cell infiltration into the CNS of EAE mice completely eradicates the disease [22]. These studies 
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highlight the dual beneficial and pathogenic role of CD8+ T cells in CNS diseases; but in HIV infection, 
CD8+ T cells have been largely associated with neuropathogenesis.  
CD8+ T cells can cause CNS damage through direct cytotoxicity or release of inflammatory cytokines 
such as IFNg or TNF as illustrated by a recent study describing a strong association between CSF CD8+ T cells 
secreting IFNg and neurocognitive impairment [23]. The frequency of CD8+ T cells in lymphocytes in CSF is 
substantially elevated during HIV infection compared to other CNS diseases [24]. Spudich et al. recently found 
that CD8+ T cells constitute the majority of white blood cells in the CSF of HIV-infected compared to 
uninfected subjects with a decreased CD4:CD8 ratio [25]. In a dramatic recently-described syndrome, some 
HIV-infected individuals initiating or maintaining ART develop cognitive impairment and encephalitis in 
association with an influx of CD8+ T cells into the brain [26-29]. This ‘CD8-T cell encephalitis’ may be a form 
of CNS immune reconstitution inflammatory syndrome, and highlights the potentially deleterious role of CD8+ 
T cells in the CNS. A newly published study reported that neurocognitive decline was associated with ongoing 
CD8+ T cell activation in CSF in HIV-infected individuals on ART, suggesting that CD8+ T cells in CSF and 
brain play a key role in HIV neuropathogenesis [30]. 
Despite the pathogenic potential of CD8+ T cells in the CNS, HIV-specific CD8+ T cells can also play a 
crucial role in mediating antiviral immunity by killing productively infected cells. The critical role of HIV-
specific CD8+ T cells in controlling viral replication has been demonstrated in the non-human primate SIV 
model of HIV infection, where CD8+ T cell depletion leads to a sharp increase in viremia [31]. In humans, 
several observations suggest that HIV-specific CD8+ T cells are important for the control of HIV replication in 
the periphery including the generation and maintenance of viral escape mutations in CD8+ T cell epitopes, the 
superior control of viral replication by certain HIV-specific clonotypes restricted by HLA-B57 and B27 [32] or 
the significant association between HIV-specific CD8+ T cell viral inhibition activity in vitro and the rate of 
CD4+ T cell loss in early HIV infection and CD4+ T cell decline in chronically infected individuals [33]. 
However, over the course of infection, HIV-specific CD8+ T cells become exhausted and lose their ability to 
control viral replication. High frequencies of SIV-specific CD8+ T cells have been detected in CSF of 
macaques chronically infected with SIV [34, 35]. HIV-specific CD8+ T cells have been also detected in CSF of 
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ART-naïve individuals but their presence has been associated with HIV dementia in chronically-infected 
subjects , suggesting that these cells are not able to contribute to the control of viral replication and participate 
in neuronal damage [36-38].  
These previous studies have been performed in chronically-infected subjects and data on CD8+ T cells 
trafficking to the CNS in acute HIV infection have not been reported. The analysis of CD8+ T cells at the 
earliest stages of HIV infection has been limited due to the difficulty to recruit individuals within days of 
acquiring HIV. The RV254/SEARCH010 cohort provided a unique opportunity to analyze CD8+ T cells in 
hyperacute infection in the CSF and periphery within the first 20 days of infection. In this cohort, we recently 
reported that HIV-specific CD8+ T cell responses present in the periphery at peak viral load have an enhanced 
capacity to kill HIV-infected cells and are associated with viral load decline and reduced seeding of the HIV 
reservoir after ART initiation (RV254 paper in review). Recent studies suggested that early ART initiation 
would preserve these effective responses in the periphery [39-42]. Preserving potent HIV-specific CD8+ T cells 
in the CNS would be useful in reducing and possibly eliminating the persistent HIV replication in ART treated 
HIV-infected individuals as it has been proposed in the SIV model [43]. However, the presence of these cells in 
hyperacute infection in the CNS and the extent to which they have the ability to limit HIV replication in the 
CNS is unknown. The enrollment of acutely HIV-infected individuals in the RV254/SEARCH010 cohort with 
the collection of PBMCs and lymphocytes from the CSF at the same time allowed us to address that question. In 
this study, we analyzed the presence of activated CD8+ T cells, their HIV specificity and function in the CSF of 
subjects in acute infection compared to the periphery.  
 
METHODS 
Study participants 
All clinical work was completed at the SEARCH clinical office in Bangkok, Thailand. Blood and CSF samples 
were collected from untreated acute HIV subjects (RV254/SEARCH010), chronic HIV (SEARCH011), and 
uninfected subjects (RV304/SEARCH013). Subjects from RV254/SEARCH010 were classified based on 
testing positive by pooled nucleic acid testing and 4th generation (4G) enzyme immunoassay (EIA): stage 1 (4th 
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gen EIA-, 3rd gen EIA-), stage 2 (4th gen EIA+, 3rd gen EIA-), stage 3 (4th gen EIA+, 3rd gen EIA+, Western 
blot-/indeterminate) [44].  4th generation EIA staging was used to estimate time of HIV exposure within the 
AHI subjects. All subjects signed the study consent forms approved by human subject review boards at 
Chulalongkorn University (Bangkok, Thailand), the Walter Reed Army Medical Center (Rockville, MD), and 
the University of California at San Francisco. Study data was collected and managed by REDCap electronic 
data capture tools hosted at VGTI-Florida [45].  
 
Fluid biomarker analyses in CSF 
CSF concentration of the neuroaxonal injury marker neurofilament light (NFL) was measured using the NF-
light enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions 
(UmanDiagnostics, Umeå, Sweden). CSF concentration of the astroglial activation marker YKL-40 was 
measured using an ELISA from R&D systems (Minneapolis, MN). All measurements were performed by 
board-certified laboratory technicians in one round of experiments using one batch of reagents. Intra-assay 
coefficients of variation were below 10%.  
 
Primary CD8+ T cell expansion for TCR repertoire and HIV specificity analyses 
Primary CD8+ T cells were isolated from the PBMCs of untreated HIV-infected subjects by fluorescence 
activated cell sorting. Isolated CD8+ T cells were expanded in RPMI supplemented as previously described 
[46]. Briefly, CD8+ T cells were expanded with PHA in 8% human serum culture medium supplemented with 
both natural and recombinant IL-2 in the presence of feeder cells (irradiated fresh PBMCs from 3 different 
donors and irradiated B-EBV cells in a 10/1 ratio). CSF pellets were expanded with under the same conditions 
for two weeks prior to CD8+ T cell isolation by cell sorting.  
 
Cell sorting and phenotypic analysis  
Thawed PBMCs or CSF were stained for surface makers at 4°C for 20 minutes with the following monoclonal 
antibodies: αCD27-FITC, αCD8-PE, αPD1-PECy7, αCD14-BV650 (BioLegend), αHLA-DR-PerCP, αCD38-
 7 
APC, αCD3-A700, αCD45RA-APCH7 (BD Biosciences), αCD4-BV605 (Life Technologies), and αCD127-
V450 (Affymetrix eBioscience). Live/dead stain with Vivid-amcyan was used to exclude dead cells from the 
sort. Cells were sorted on a BD Facs Aria II (BD Biosciences) and analyzed with FlowJo software (Treestar).  
 
Intracellular staining (ICS) with CD8+ T cells  
B-EBV lines were generated for each donor by culturing PBMCs in RPMI, 20% fetal bovine serum (FBS), 
20nM FK506 (AG Scientific), and Ebstein-barr virus (EBV)-containing supernatant from the virus-producing 
B95.8 marmoset cell line (ATCC) at an MOI of 100. B-EBV cell lines were then plated in the presence of 0.5-5 
mg/mL HIV Clade AE peptide pools, 1 μg/mL staphylococcal enterotoxin B (Sigma-Aldrich) or DMSO 
overnight. Peptide pools were made with 20 peptides per pool of HIV PTE and HIV Consensus A peptides (gag, 
pol, nef, env) at 15 amino acids in length. The peptides were obtained through the AIDS Reagent Program, 
Division of AIDS, NIAID, and NIH. Expanded primary CD8+ T cells were added to the loaded B-EBV (2:1) 
and co-stimulated with 1 μg/μL αCD28/CD49d (BD Biosciences). Stimulated cells were immediately treated 
with GolgiPlug protein transport inhibitor (BD Biosciences) to prevent secretion of cytokines and incubated at 
37°C for 12 hours. After incubation, cells were washed and stained with αCD8- FITC, αCD3-Pacific Blue (BD 
Biosciences), and αCD20-PECy7 (BioLegend) prior to fixation/permeabilization (2% formaldehyde) and 
intracellular staining with αIFNγ-APC (BD Biosciences). Live/dead stain with Vivid-amcyan was used to 
exclude dead cells from the analysis.  
 
TCR Vbeta repertoire analysis 
We analyzed the T-cell receptor Vbeta repertoire by flow cytometry using the IOTest® Beta mark (Beckman 
Coulter) in conjunction with αCD8-Pacific Blue (BD Biosciences). Stained CD8+ T cells were run on an LSRII 
flow cytometer using DiVA software (BD Biosciences) and analyzed with FlowJo (Treestar).  
 
Gene expression analysis  
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CD8+ T cells were sorted from the CSF samples into 96 well plates at 100 cells/well to perform the 
Fluidigm’s Biomark Assay. Assays (Primers and Probes) were designed using the Roche Universal Probe 
Library Assay Design Center (www.universalprobelibrary.com) and were designed to detect multiple 
transcripts, without respect to isoform prevalence. Cells were sorted directly into PCR plates and immediately 
frozen. RNA was reverse transcribed and amplified in a single-step RT-STA (Specific Template Amplification) 
using a pool of all the primer sets and with the Superscript III Platinum One-Step qRT-PCR Kit (without ROX) 
(Life Technologies, Grand Island, NY). The STA was carried out for 18 cycles of 95°C for 15 seconds and 
60°C for 4 minutes. Unincorporated primers and any generated non-specific single-stranded products were then 
removed by an Exonuclease I (E. coli).(NEB, Ipswich, MA) step. High-throughput qPCR on the pre-amplified 
samples was performed on a 96.96 BioMark™ Dynamic Array (Fluidigm, South San Francisco, CA) [47] for 40 
cycles (15 seconds at 95°C, 5 seconds at 70°C, 60 seconds at 60°C). The same primer set used in the RT-STA 
was used for the probe-based qPCR. Threshold cycle (CT) values were calculated by the Real-Time PCR 
Analysis Software (Fluidigm) and failed reactions were discarded from the analysis. 
 
Statistical analyses 
Neurological testing and neuroninflammatory markers were previously evaluated and available for all CSF 
specimens studied. P values were calculated using One-Way ANOVA and Kruskal-Wallis with post-hoc Dunn 
multiple comparison analysis for group comparisons. Statistical analysis for correlations was performed using 
Spearman rank and the 2-tailed paired or unpaired t-test with 95% confidence intervals, correlation and linear 
regression statistical analysis using the Prism 5 for Macintosh (GraphPad software). 
 
RESULTS 
Clinical Composition  
We evaluated 57 individuals from uninfected (n=8), acute HIV infection (AHI) stage 1/2 (n=9), AHI stage 3 
(n=17) and chronic HIV infection (CHI) (n=23) groups similar in demographic variables. All subjects were 
ART-naïve and subject demographic details are presented in Table 1. The acutely HIV-infected subjects were 
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recruited during the earliest stages of acute infection within the first 20 days of acquiring HIV corresponding 
to pre-peak to peak viremia, as previously described [48]. AHI stages 1 and 2 were grouped together since both 
stages are before peak viremia and no differences were found between the groups (data not shown) whereas 
AHI stage 3 correspond to peak viremia. Untreated chronically HIV-infected subjects had acquired HIV more 
than 2 years prior to enrollment and displayed elevated viral loads in the periphery and CSF. There was no 
significant difference in age between any of the groups. All subjects were fully characterized by demographic 
and clinical variables and underwent simultaneous lumbar puncture and blood draw.  
 
Activated CD8+ T cells are elevated in the CSF in acute infection 
Viral loads in the plasma and CSF of subjects in acute and chronic stages were measured. Subjects in AHI stage 
3 had significantly elevated viral loads in the plasma compared to subjects in AHI stage 1/2 and tended to have 
also elevated plasma viral load compared to CHI subjects although not significant (Fig. 1A). CSF viral loads 
were higher in CHI subjects compared to AHI stage 1/2 subjects, but not significantly different than AHI stage 
3 subjects. In order to analyze the CD8+ T cell response in early acute HIV infection compared to late stages of 
infection, cells from CSF were examined by flow cytometry. The number of total CSF CD8+ T cells was 
highest in the chronic HIV subjects compared to both the acute and uninfected groups but increased numbers of 
CD8+ T cells were detected already in AHI stage 3 (Fig. 1B). As expected, there were fewer CD4+ T cells than 
CD8+ T cells in the CSF across all HIV-infected groups (Supp. Fig. 1A). Furthermore, the frequency of 
activated CD8+ T cells in the CSF characterized by HLA-DR+ CD127- was significantly elevated in CHI 
subjects compared to all other groups but AHI stage 3 subjects already showed increased activated CD8+ T cell 
frequencies compared to AHI stage 1/2 subjects and uninfected (Fig. 1C,D). Similarly, the frequency of 
activated CD4+ T cells was most elevated in CHI subjects but already started to be elevated in AHI stage 3 
(Supp. Fig. 1B). Further phenotypic analyses revealed that CD127 expression, the alpha chain of IL-7 receptor 
as a marker of survival potential, decreased on CD8+ and CD4+ T cells during acute infection and was 
significantly lower in the chronic stage (Fig. 1E, Supp. Fig. 1C). Full characterization of the CD8+ T cell 
phenotype revealed no significant difference between the memory CD8+ T cell subsets naïve 
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(CD45RA+CD27+), TEMRA (terminal differentiated effector memory) (CD45RA+CD27-), TTM 
(transitional memory) (CD45RA-CD27+), or TEM (effector memory) (CD45RA-CD27-) in the CSF of the 
different groups (Supp. Fig. 2). Together, these data demonstrate a massive infiltration of activated CD8+ T 
cells into the CNS as early as AHI stage 3 infection with aggravation of the activation status and loss of survival 
potential in the chronic phase of HIV infection.   
 
CSF activated CD8+ T cells are associated with CSF viral load and neuroinflammatory markers in acute HIV 
infection 
To investigate whether the activation states of CD8+ T cells in AHI stage 3 and chronic infection were 
associated with a pathogenic or beneficial effect on viral replication in the CNS, we analyzed the association 
between the frequency of activated CD8+ T cells in the CSF with viral load and levels of common 
neuroinflammatory markers measured in the CSF. In AHI stage 3, the frequency of activated CD8+ T cells in 
the CSF was strongly associated with CSF viral load (r=0.66, p=0.004) (Fig. 2A), but not with plasma viral load 
(Supp. Fig. 3A). In contrast, the frequency of activated CD8+ T cells in chronic subjects did not correlate with 
viral loads in the CSF but did correlate with plasma viral load (r=0.45, p=0.035) (Fig. 2B, Supp. Fig. 3B). When 
analyzing the association with neuroinflammatory markers in the CSF, we found that the frequency of activated 
CD8+ T cells in CSF from AHI stage 3 subjects was positively correlated with CSF levels of neopterin (r=0.53, 
p=0.005), interferon-gamma induced protein 10 (IP-10) (r=0.47, p=0.016), and soluble CD163 (r=0.75, 
p<0.0001), all synthesized by activated myeloid cells (Fig. 2C). These correlations were not seen in chronic 
HIV infection (Supp. Fig. 3C). A similar trend was observed with the frequency of activated CD4+ T cells in 
the AHI stage 3 CSF and neuroinflammatory markers neopterin and IP-10 and a significant correlation with 
CD163 (Supp. Fig. 3D), suggesting that the neuroinflammatory arkers present in the CNS compartment during 
acute HIV infection at peak viremia are attracting and/or activating CD8+ T cells and to a lesser extend CD4+ T 
cells in the CNS. Importantly, CSF levels of neuroinflammatory markers common in later stages of 
neuroinflammation and neuronal damage, neurofilament light chain (NFL) and YKL-40, were positively 
correlated with frequency of activated CD8+ T cells in CSF of chronic subjects  (r=0.58, p=0.007, and r=0.45, 
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p=0.049 repectively) (Fig. 2D). These neuroinflammatory markers did not correlate with frequency of 
activated CD8+ T in the CSF of acute infection or CD4+ T cells in CSF of chronic subjects (Supp. Fig. 4A,B). 
These data suggest that the presence of high numbers of activated CD8+ T cells in the CNS compartment in 
AHI stage 3 is mainly driven by the presence of HIV antigens in the CNS and the inflammatory response of 
microglia and myeloid cells. The presence of higher numbers of activated CD8+ T cells in CSF during chronic 
infection is not driven by antigen levels in the CNS or neuroinflammation but rather by plasma HIV antigen 
levels and are associated with neuronal damage. Therefore, these results suggest that although elevated in both 
acute and chronic infection, activated CD8+ T cells have a pathogenic role in chronic infection in line with 
previously work, whereas activated CD8+ T cells are responding to HIV replication in the CNS in acute HIV 
infection. 
 
CSF CD8+ T cell associated genes are upregulated in acute HIV infection 
To assess the potential beneficial role of CD8+ T cells in CSF during acute HIV infection, we measured the 
gene expression profile of CD8+ T cells in CSF from acute and chronic subjects using a high-throughput 
nanofluidic qPCR system. The system allowed us to detect 48 genes simultaneously from the very few CD8+ T 
cells present in the CSF. Gene expression was normalized to a reference gene and fold change in gene 
expression in CD8+ T cells CSF of HIV-infected individuals were calclulated compared to CD8+ T cells in 
CSF of uninfected controls. Genes associated with CD8+ T cytolytic effector function, cell cycle, T cell 
receptor (TCR) signaling, and transcription factors were significantly elevated in AHI stage 3 CSF CD8+ T 
cells compared to CSF CD8+ T cells from AHI stage 1/2 and to chronic infection (Fig. 3). Increased expression 
of these genes could be seen as early as AHI stage 1/2, however, by chronic stage the expression of these 
pathways was downregulted compared to uninfected controls suggesting CD8+ T cell exhaustion. These results 
demonstrate a very distinct gene expression profile of CD8+ T cells present in the CSF in acute and chronic 
infection supporting the distinct role of these cells suggested by the associated with different neuroinflammatory 
markers in the CSF described above. These data suggest that overall activation and upregulation of critical 
CD8+ T cell associated genes begins as early as AHI stage 1/2 and peaks at AHI stage 3, suggesting that CD8+ 
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T cells in CSF during acute HIV infection have increased proliferation, effector functions and have been 
TCR triggered and are likely to respond to HIV antigen presence to control viral replication in the CNS. In 
contract, their counterparts in chronic infection displayed a very distinct blunted gene expression profile 
suggesting a dysfunctional state unable to contribute to local viral replication.  
 
CSF CD8+ T cells express a unique TCR Vbeta repertoire compared to activated CD8+ T cells in the periphery 
To determine whether the presence of activated CD8+ T cells in the CSF is unique to the CNS comprtment and 
is not only a passive migration of peripheral activated CD8+ T cells, we analyzed the TCR Vbeta repertoire of 
CD8+ T cells from AHI stage 3 subjects in CSF, and activated and non-activated CD8+ T cells in the periphery. 
The results from the 8 AHI stage 3 subjects analyzed showed that CD8+ T cells in CSF expressed a unique TCR 
repertoire profile compared to the periphery (Fig. 4A). The TCR Vbeta repertoire diversity was significantly 
lower in the CD8+ T cells in CSF compared to activated and non-activated CD8+ T cells in peripheral blood 
mononuclear cells (PBMCs) (Fig. 4B). Importantly, CSF CD8+ T cells showed up to 40% unique Vbeta usage 
compared to their matched activated CD8+ T cells from the periphery (Fig. 4C). Despite CSF CD8+ T cells 
expressing lower TCR repertoire diversity compared to the periphery, they displayed a unique TCR Vbeta 
repertoire in the CSF during acute infection reflecting differences in compartmentalization.  
 
HIV-specific CD8+ T cells are present in the CSF in acute infection  
The presence of HIV-specific CD8+ T cells in CNS is expected to have a beneficial effect on neuronal damage 
by killing HIV infected cells and decreasing HIV replication in the brain. In order to determine the presence and 
specificity of CD8+ T cells in CSF, we generated CD8+ T cell lines and autologous B-EBV cell lines as 
previously described [46] from 10 AHI stage 3 subjects. B-EBV cells are used as antigen presenting cells and 
loaded with peptide pools for gag, pol, env, and nef. These pools were selected based on potential T cell 
epitopes common in HIV clade AE, which is dominant in Thailand. HIV peptide loaded B-EBV cells were then 
co-cultured with donor matched CD8+ T cells from either the CSF or periphery (activated and non-activated 
CD8+ T cells) and IFN-gamma production was measured. HIV-specific CD8+ T cells were present in high 
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frequency in the activated CD8+ T cell population in the CSF and PBMCs, but not in the non-activated 
CD8+ T cell population in the PBMCs (Fig. 5A). When assessing the specific peptide recognized by CD8+ T 
cells from CSF ad PBMCs in the same subjects, we found that CD8+ T cells were directed against shared, but 
also unique HIV epitopes in CSF compared to periphery (Fig. 5B). These results show that a high proportion of 
HIV-specific CD8+ T cells are expanding in acute HIV infection and are present in the CNS compartment. 
These results also demonstrate that the CD8+ T cell specificity differs between the two compartments in acute 
infection and provide evidence for the presence of HIV-specific CD8+ T cells able to control viral replication in 
the CNS. Altogether, these results provide evidence for a distinct role of CD8 T cells in acute and chronic 
infection in the CNS compartment, with activated CD8+ T cells associated with neuropathogenesis in chronic 
infection whereas in acute infection, activated CD8+ T cells in the CSF exhibit enhanced functional gene 
expression, a unique repertoire and contain HIV-specific CD8+ T cells, suggesting that these cells could play a 
beneficial role of controlling HIV replication and preventing CNS damage if ART was initiated at that stage. 
 
DISCUSSION 
Despite the large presence of CD8+ T cells in the CNS during early HIV infection, their role in 
neuropathogenesis remains unknown. In this study, we provide new information on (i) the phenotype and 
activation state of CD8+ T cells present in the CSF in the earliest stages of acute HIV infection, (ii) determine 
how the CD8+ T cells change throughout infection from acute to chronic infection in ART naïve subjects, (iii) 
how the activated CD8+ T cells relate to neuroinflammatory markers in the different stages of infection, (iv) 
and elucidate on the HIV specificity and potential beneficial role of CD8+ T cells in acute infection. Previously, 
Valcour et. al. detected HIV RNA in the CSF of subjects from this hyperacute infection cohort as early as 8 
days after estimated HIV infection and identified elevated neuroinflammatory markers in the CSF in these 
acutely-infected subjects [49]. Here, we found positive correlations with the frequency of activated CD8+ T 
cells in the CSF to early biomarkers of immune activation in the CNS (CSF neopterin, CSF IP-10, and CSF 
CD163) as well as CSF viral load at peak viremia in acute infection.  These early markers of CNS inflammation 
did not correlate with activated CD8+ T cells in chronically-infected subjects, where levels of NFL and YKL-
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40, biomarkers of neuroaxonal injury and astroglial activation in chronic CNS inflammation and 
neurodegeneration correlated with the frequency of activated CD8+ T cells in the CSF. These results depict a 
very distinct immune response and inflammatory environment between acute and chronic infection and suggest 
that activated CD8+ T cells are recruited early in acute HIV infection responding to early neuroinflammatory 
markers in the CNS and might play a beneficial role in preventing neuronal damage if viral replication is halted 
at that stage by ART by killing HIV infected cells. Indeed, we recently demonstrated that activated CD8+ T 
cells in the periphery were fully differentiated into effector cells at peak viremia and were able to decrease viral 
production and reduce HIV reservoir seeding after ART initiation at that stage of acute HIV infection (paper 
submitted).  
 
Evaluating T cells in CSF is typically limited by the small amount of cells that can be extracted from the 
CSF and is not equivalent to analyzing brain tissue, but it is the best available cells that we have access to assess 
the immunologic status of the brain in these acutely-infected individuals. We developed novel techniques that 
allowed for the comprehensive characterization of CD8+ T cells on a very small number of cells detected in the 
CSF. Our data demonstrates major differences in CD8+ T cells present in the periphery compared to the CSF 
and highlight the importance of analyzing CSF cells to investigate their role in CNS rather than PBMCs. 
Additionally, the frequency of activated CD8+ T cells in the CSF of acute stage 3 subjects positively correlated 
with the CSF viral load, but not the plasma viral load, indicating differences between CSF and plasma markers 
and the potentially inaccuracy of using plasma markers as accurate reflections of CNS activities. Our group 
previously demonstrated phenotypic, gene expression and functional differences in CD8+ T cell profiles in the 
periphery of acutely and chronically HIV-infected subjects [50]. In the current study, we found that activated 
CD8+ T cells exhibited distinct gene expression pathways associated with CD8+ T cells activation such as cell 
cycle, TCR signaling, effector function in the CSF during acute infection compared to chronic infection. This 
elevated activation state was not as apparent in CSF CD4+ T cells during acute infection.  
The IL-7 cytokine plays an important role in the activation of CD8+ T cells in response to viral infection 
as it promotes T cells survival and potentiates cytolytic activity and perforin accumulation intracellularly [51-
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53]. It has been well documented that expression of the IL-7 receptor alpha chain (CD127) is reduced on 
CD8+ T cells in HIV-infected individuals and partial recovery is observed in subjects that initiate ART [54]. 
Report have also shown in chronically-infected individuals that CD8+ T cells with lower CD127 expression 
were unable to become activated lymphoblasts and upregulate CD25 [55]. Previously, we demonstrated that the 
expression of CD127 on HIV-specific CD8+ T cells in the periphery in acute HIV infection was associated with 
a lower viral set point in untreated chronic infection. Here we observed a significant decrease in CD127 
expression on activated CD8+ T cells in the CSF of chronic subjects.  Interestingly, this decrease in CD127 
expression appears as early as AHI stage 1/2 eventhough the frequency of activated CD8+ T cells is not 
elevated yet and could be an early sign of impaired CD8+ T cell response. We also noticed a slight increase in 
PD-1 expression, a known marker of T cell activation and exhaustion (data not shown). Together, these data 
show that the profile of CD8+ T cells are being altered very early on in acute infection that could explain the 
loss of virus-specific CD8+ T cell response that is seen in chronic infection as viral replication persists. 
Therefore, these observations suggest the very early initiation of ART may prevent these permanent changes in 
CD8+ T profile and preserve CD8+ T cell antiviral response in the CNS. 
We have previously shown that chronic inflammation results in a dramatic clonal focusing of HCMV-
specific CD8+ T cells in the synovial fluid compared to periphery in rheumatoid arthritis individuals suggesting 
that inflammation in tissues is reflected by T cell selection more significantly than in the PBMCs [46]. In ART-
naïve individuals, activated HIV-specific CD8+ T cells are maintained at high frequency due to constant HIV 
antigen stimulation. Here we show that as early as in acute infection, T cell clonotypes are expanded as CD8+ T 
cells in CSF exhibited unique Vbeta usage compared to their matched activated CD8+ T cells from the 
periphery. These data suggest that CD8+ T cells in CSF exhibit a restricted unique TCR repertoire that allows 
for the longitudinal follow up of these clones over time and provide the rationale to assess whether persisting 
clonotypes in CSF under ART associate with residual neuroinflammation. Future studies will determine if 
CD8+ T cell clonotypes that persist after ART in CSF are associated with persistent CNS neuroinflammation 
injury.  
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The presence of HIV-specific CD8+ T cells in CNS is expected to have a beneficial effect on 
neuronal damage by killing HIV infected cells and decreasing HIV replication in the brain. Little is known 
about the frequency of CD8+ T cells recognizing HIV antigens over the course of HIV infection especially in 
the CNS. A recent study suggested that inflammatory cytokines present during untreated chronic HIV infection 
triggers proliferation and expression of activation markers in CD8+ T cells in the periphery independent of 
antigen specificity [56]. These bystander cells might be unable to eliminate HIV-infected cells. However, we 
demonstrated here that HIV-specific CD8+ T cells are present in acute HIV infection already at peak viremia in 
the CSF and ART initiation in acute infection could lead to the preservation of these effector HIV-specific 
CD8+ T cells and could be critical for reducing the residual HIV replication in the CNS. Here, we demonstrated 
not only that HIV-specific CD8+ T cells are present in the CSF, but that they respond to unique HIV epitopes in 
the CSF compared to the CD8+ T cells in the periphery. This data along with the specific TCR Vbeta repertoire 
suggest very early infiltration and local expansion of HIV-specific CD8+ T cells in the CNS that may be 
interacting with unique HIV epitopes that are present in the CNS and not in the periphery. Our data demonstrate 
trafficking of highly activated and HIV-specific CD8+ T cells to the CNS within the first weeks after HIV 
exposure and provide the rationale to analyze CSF cell populations rather than PBMCs to understand immune 
repsonses in the CNS. Determining whether CD8+ T cells can play a beneficial role in the CNS of HIV-infected 
subjects will be determined by future longitudinal studies in this unique acute infection cohort initiating ARVs 
in the earliest stage of infection infection  as it will determine if early ART initiation will preserve beneficial 
HIV-specific CD8+ T cells in the brain, that have the potential to control viral replication. These findings will 
be critical in targeting the HIV reservoirs that persists in the CNS despite ART.  
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Figure and Table Captions 
Table 1. Demographic and clinical parameters of study participants. CD4 T cell count is cells/mm3 in 
plasma.  Abbreviations: AHI - acute HIV infection, CHI – Chronic HIV infection. Acute HIV-infected subjects 
were classified based on testing positive by pooled nucleic acid testing and 4th generation (4G) enzyme 
immunoassay (EIA): stage 1 (4th gen EIA-, 3rd gen EIA-), stage 2 (4th gen EIA+, 3rd gen EIA-), stage 3 (4th 
gen EIA+, 3rd gen EIA+, Western blot-/indeterminate) *Days of infection is estimated time of exposure and 
enrollment. If a range of dates was provided, the mean was used.  
 
Figure 1. Activated CD8+ T cells are elevated in the CSF during acute HIV infection. A. CSF viral load in 
acute HIV infection Stage1/2, acute HIV infection Stage 3 and chronic HIV infection (CHI) samples. Limit of 
detection 100 viral copies/ml. B. Number of CD8+ T cells per mL of CSF in the different groups of donors. C. 
Representative dot plots of activated CD8+ T cells defined by CD38+ CD127- in the CSF of a representative 
subject in the different groups. D. Frequency of activated CD8+ T cells (CD38+, CD127-) within the CD8+ T 
cells in CSF in the different groups. E. Frequency of CD127+ CD8+ T cells within CD8+ T cells in CSF in the 
different groups. Uninfected subjects (white), AHI Stage 1/2 subjects (light grey), AHI Stage 3 subjects (dark 
grey) and CHI subjects (black). Asterisks denote different P values: *P< 0.05; **P < 0.005; *** < 0.0001.  
 
Fig 2. Activated CD8+ T cells in CSF from AHI subjects positively correlates with CSF viral load and 
CSF markers of neuroinflammation. A. Correlation of activated CD8+ T cells with viral load in the CSF in 
AHI Stage 3 subjects. B. Correlation of activated CD8+ T cells with plasma viral load in CHI subjects plasma 
viral load in chronic subjects. C.  Frequency of CSF activated CD8+ T cells in AHI Stage 1/2 and 3 correlates 
with CSF neuroinflammatory markers neopterin, IP-10, and CD163. D. Frequency of activated CD8+ T cells in 
the CSF of CHI subjects correlates with CSF neurofilament and YKL-40. 
Fig 3. Gene expression of CD8+ T cells in the CSF of acute and chronic HIV infected subjects. Targeted 
gene expression profile of 48 genes by multiplex qPCR involved in cell cycle, transcription factors, CD8 
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effector functions, and TCR signaling pathways for the CD8+ T cells in the CSF of AHI stage 1/2, AHI stage 
3, and CHI subjects compared to uninfected subjects. Scale represents fold change in gene expression of 100 
CD8 T cells in the analyzed group compared to uninfected subjects.  
 
Fig 4. TCR Vbeta repertoire of CD8+ T cells in CSF and PBMCs from 8 AHI stage 3 subjects. A. 
Frequency of Vbeta family usage of CD8+ T cells per AHI stage 3 subject (n=8) from the CSF, activated CD8+ 
T cells in PBMCs (PBMC ACT), and non-activated CD8+ T cells in PBMCs (PBMC nonACT). B. Number of 
Vbeta families out of the 24 Vbeta families tested that were expressed on CD8+ T cells from CSF, activated and 
non-activated CD8+ T cells in PBMCs per subject in each compartment, *p<0.05,***p<0.0005. C. Frequency 
of Vbeta families unique to the CSF compared to the PBMCs for each AHI stage 3 subject analyzed.  
 
Figure 5.  Frequency of HIV-specific CD8+ T cells in the CSF and PBMCs in acute HIV infection. A. 
Frequency of activated CD8+ T cells from AHI stage 3 subjects (n=10) expressing IFNγ in response to 
stimulation with Gag, Pol, Env, and Nef in activated CD8+ T cells in the CSF (CSF ACT), activated CD8+ T 
cells in the periphery (PBMC ACT), and non-activated CD8+ T cells in the periphery (PBMC non-ACT), 
*p<0.05, **p<0.005. B. Frequency of HIV-specific CD8+ T cells that responded to peptide pool stimulation (4-
5 pools per HIV protein) in the CSF and activated PBMCs (ACT) by measuring IFNγ production. Grey bar 
color represents HIV-specific CD8+ T cell responses that were unique to either the CSF or PBMCs and black 
represents responses that were shared by both compartments.  
 
Supplementary Fig 1. Frequency of activated CD4+ T cells in the CSF. A. Number of CD4+ T cells in the 
CSF of uninfected subjects (white), AHI Stage 1/2 subjects (light grey), AHI Stage 3 subjects (dark grey) and 
CHI subjects (black). B. Frequency of activated CD4+ T cells within the CD4+ T cells in CSF in the different 
groups. C. Frequency of CD127+ CD4+ T cells within CD4+ T cells in CSF in the different groups. Asterisks 
denote different P values: *P< 0.05; **P < 0.005; *** < 0.0001.  
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Supplementary Fig 2. Distribution of CD8+ T cell memory subsets in CSF. Proportions of naïve, 
TEMRA=terminal differentiated effector memory, TTM=Transitional memory, TEM=effector memory CD8+ T 
cells in CSF in the different groups: uninfected subjects (white), AHI Stage 1/2  subjects (light grey), AHI Stage 
3 subjects (dark grey) and CHI subjects (black). 
 
Supplementary Fig 3. Correlation of activated CD8+ and CD4+ T cells in the CSF with viral load and 
neuroinflammatory marker. A. Frequency of activated CD8+ T cells in the CSF does not correlate with 
plasma viral load in acute HIV infection. B. Frequency of activated CD8+ T cells in the CSF does not correlate 
with CSF viral load in chronic infection  C. Frequency of activated CD8+ T cells in CHI subjects showed no 
correlations to common early neuroinflammatory markers (IP-10, neopterin) in the CSF.  D. Frequency of 
activated CD4+ T cells in the CSF does not significantly correlate with neuroinflammatory markers neopterin or 
IP-10 in acute subjects (AHI Stage 1/2 and 3), but does correlate with CD163.  
 
Supplementary Fig 4. Correlation of activated CD8+ and CD4+ T cells in the CSF with viral load and 
neuroinflammatory marker. A. Frequency of activated CD8+ T cells in the CSF does not correlate with NFL, 
a marker of neuroaxonal injury or YKL-40, a marker of astroglial activation in acute HIV infection. B. 
Frequency of activated CD4+ T cells does not correlate with NFL or YKL-40 levels in CHI subjects. 
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